•  

Posts Tagged: lab-free molecular diagnostic testing

Xagenic announces second closing of $25.5M Series B financing

TORONTO, July 14, 2014 - Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, has announced a second closing of its recently announced Series B financing, bringing the total raised in this round to $25.5 million. In conjunction with this closing, new investor BDC Capital joined as an investor and Dion Madsen, senior managing partner at BDC Capital, will join Xagenic's Board of Directors. From our archives: MaRS Innovation's lead start-up completes $20 million ... Read more

Frost & Sullivan awards Xagenic award for new product innovation leadership

Market research company lauds start-up for developing a breakthrough workflow while dramatically improving point-of-care diagnosis (MOUNTAIN VIEW, Calif) May 20, 2014 — Based on its recent analysis of the point-of-care diagnostics market, Frost & Sullivan recognizes Xagenic Inc. with the 2014 North America Frost & Sullivan Award for New Product Innovation Leadership. Xagenic’s revolutionary product, the Xagenic X1™ system, is a point-of-care platform with intuitive features to provide lab-free molecular diagnostic testing. It is unique as a low-cost, simple, rapid sample-to-answer desktop instrument, ... Read more